• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

    12/4/24 8:30:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email

    DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates.

    Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT
      
    Pre-Registration: Participants can pre-register for the conference call here:
      
     Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
      
    Dial In:Those who choose not to pre-register can access the live conference call by dialing the following and requesting the SeaStar Medical call:
     866-777-2509 within the U.S.
     412-317-5413 from outside the U.S.
      

    The live webcast of the conference call also will be available here. A replay of the call will be available for 48 hours beginning two hours after its completion by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 3855739. The webcast will also be archived here.

    About SeaStar Medical

    SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

    Contact:

    Alliance Advisors IR

    Jody Cain

    (310) 691-7100

    [email protected]

    # # #



    Primary Logo

    Get the next $ICU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When is the SeaStar Medical conference call scheduled?

      The conference call will take place on December 11, 2024, at 4:30 p.m. ET.

    • How can participants join the conference call?

      Participants can pre-register for the conference call via a provided link to gain immediate access.

    • What are the dial-in numbers for the SeaStar Medical conference call?

      Those in the U.S. can dial 866-777-2509, while international callers can reach 412-317-5413.

    • Will there be a replay available for the conference call, and how can one access it?

      A replay of the call will be available for 48 hours after its completion by dialing specific numbers based on the caller's location.

    • What is the primary focus of SeaStar Medical as a company?

      SeaStar Medical is focused on developing technologies that reduce hyperinflammation effects on vital organs.

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Towne Bradford K claimed ownership of 15,500 shares (SEC Form 3)

    3 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    9/9/25 5:16:55 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Chung Kevin bought $8,000 worth of shares (10,000 units at $0.80), increasing direct ownership by 21% to 58,184 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/25/25 6:21:34 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

    Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry presented on Saturday, September 27, 2025, at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation highlighted the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening

    9/29/25 8:36:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

    Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the independent Data Safety Monitoring Review Board (DSMB) has recommended the continuation of the NEUTRALIZE-AKI pivotal trial of the Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (C

    9/24/25 4:22:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

    DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical and its research collaborators at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation will highlight the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Safety data will also be presented. A second accepted

    9/23/25 8:23:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Chung Kevin bought $8,000 worth of shares (10,000 units at $0.80), increasing direct ownership by 21% to 58,184 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/25/25 6:21:34 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Baird Jennifer A converted options into 2,667 shares and bought $4,174 worth of shares (10,000 units at $0.42), increasing direct ownership by 83% to 28,000 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    7/2/25 7:32:54 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    SEC Filings

    View All

    SEC Form 424B5 filed by SeaStar Medical Holding Corporation

    424B5 - SeaStar Medical Holding Corp (0001831868) (Filer)

    10/14/25 6:17:23 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update

    8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    9/29/25 4:28:05 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Holding Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    9/24/25 5:00:28 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

    DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S.1 (646) 307-1963 from outside the U.S.

    8/7/25 10:00:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

    DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

    5/7/25 10:00:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

    DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic

    3/27/25 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care